Supira Medical Secures $120M Series E Funding, Bolsters Clinical Program
Deal News | Mar 26, 2025 | PR Newswire Cision Supira Medical, Inc.
Supira Medical, Inc., a Shifamed portfolio company based in Los Gatos, California, has completed an oversubscribed Series E financing round, raising $120 million to advance its percutaneous ventricular assist device (pVAD) technology. The round was led by notable investors Novo Holdings and Qatar Investment Authority, along with additional strategic partners and existing investors like Cormorant Asset Management. Funds will be allocated towards expanding Supira's clinical programs for high-risk percutaneous coronary intervention (HRPCI) and cardiogenic shock (CS), including a U.S. Pivotal Study for HRPCI aimed at obtaining FDA pediatric market authorization. Supira also completed enrollment for its U.S. SUPPORT I Early Feasibility Study involving 15 patients across four clinical sites. The company aims to address significant unmet needs in heart failure treatment and improve peripheral organ perfusion through its advanced, low-profile, high-flow technology. Piper Sandler served as the financial advisor, while Sidley Austin LLP served as legal counsel for the transaction. Additionally, Dr. Christopher Shen, a partner at Novo Holdings, joined the board, signifying further trust and collaboration in Supira's mission.
Sectors
- Medical Devices
- Venture Capital & Private Equity
- Healthcare
Geography
- United States – Supira Medical is conducting its clinical trials in the U.S. and is seeking regulatory approval from the FDA.
- Qatar – Qatar Investment Authority, one of the lead investors, is based in Qatar.
- Denmark – Novo Holdings, another lead investor, is affiliated with the Novo Nordisk Foundation based in Denmark.
Industry
- Medical Devices – The article focuses on Supira Medical's efforts to develop and market advanced pVADs, which are critical for heart failure treatment.
- Venture Capital & Private Equity – The involvement of investment firms such as Novo Holdings and Qatar Investment Authority highlights the article's relevance to the venture capital and private equity industry.
- Healthcare – Supira Medical is engaged in providing advanced healthcare solutions, particularly in the interventional cardiology field, addressing unmet needs in cardiogenic shock and HRPCI.
Financials
- $120M – Amount raised in the Series E financing round by Supira Medical.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Supira Medical, Inc. | Target Company | Company | A clinical-stage company developing next-generation pVADs for high-risk cardiac patients. |
| Novo Holdings | Investor | Company | A world-leading life sciences investor and part of the Novo Nordisk Foundation. |
| Qatar Investment Authority (QIA) | Investor | Government | The sovereign wealth fund of the State of Qatar, managing state reserve funds with a diversified investment portfolio. |
| Piper Sandler | Financial Advisor | Company | Served as exclusive financial advisor to Supira Medical in this financing transaction. |
| Sidley Austin LLP | Legal Advisor | Company | Provided legal counsel to Supira Medical for the Series E financing round. |
| Dr. Nitin Salunke | President and CEO | Person | Leads Supira Medical in its mission to develop and market advanced cardiac support devices. |
| Dr. Christopher Shen | Board Member | Person | Partner at Novo Holdings and new member of Supira Medical's Board of Directors. |
| Shifamed, LLC | Parent Company | Company | A medical innovation hub and parent company to Supira Medical. |